Endo Total Liabilities and Share Holders Equity 2024-2025 | NDOI

Endo total liabilities and share holders equity from 2024 to 2025. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.

Endo Total Liabilities and Share Holders Equity 2024-2025 | NDOI

Endo total liabilities and share holders equity from 2024 to 2025. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$75.3B
Zoetis (ZTS)$68.1B
Takeda Pharmaceutical (TAK)$46.9B
Daiichi Sankyo, - (DSNKY)$43.1B
BeOne Medicines - (ONC)$29.6B
Sandoz Group AG (SDZNY)$25B
Summit Therapeutics (SMMT)$18.1B
Merck (MKKGY)$16.5B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.2B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.2B
Stevanato Group S.p.A (STVN)$7.8B
Corcept Therapeutics (CORT)$7.6B
Madrigal Pharmaceuticals (MDGL)$6.9B
Grifols, S.A (GRFS)$6.7B
Ionis Pharmaceuticals (IONS)$6.7B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.3B
Soleno Therapeutics (SLNO)$4.2B
Hypermarcas (HYPMY)$3.2B
Crinetics Pharmaceuticals (CRNX)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$2B
BioCryst Pharmaceuticals (BCRX)$1.8B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.7B